Regeneron Pharmaceuticals Inc. announced on Tuesday that it signed an agreement with Fujifilm Diosynth Biotechnologies to produce and supply Regeneron's commercial biologic medicines at its campus in North Carolina. The total investment, including technology transfer and a ten-year term, is projected to top $3 billion, according to Regeneron's press release.
"We take our role seriously, and our decision to work with Fujifilm reflects our belief that they will meet our high standards and grow with us. We are excited about this unique relationship, and we are already working to bring capacity online at Fujifilm’s biologics manufacturing facility in Holly Springs, North Carolina," Regeneron Executive Vice President Daniel Van Plew noted.
Furthermore, Regeneron said that its ongoing and planned investment in production and infrastructure in New York and North Carolina is estimated to exceed $7 billion.
